Previous 10 | Next 10 |
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-12 08:53:13 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune: Drug Approval Now Imminent? FDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4 Seeking Alpha’s Quant Rating...
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4 th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18 th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. -...
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with ...
2024-03-07 13:13:56 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune: Drug Approval Now Imminent? FDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4 Adaptimmune projects sarcoma franch...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
2024-03-06 09:29:11 ET Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer John Lun...
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4 th , 2024 Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Co...
2024-03-05 11:53:29 ET More on Adaptimmune Adaptimmune: Drug Approval Now Imminent? FDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4 Adaptimmune projects sarcoma franchise to deliver US peak year sales up to $400M Read the full article...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...